Silexion Therapeutics (SLXN) Competitors $5.06 -2.04 (-28.73%) Closing price 09/9/2025 03:57 PM EasternExtended Trading$5.22 +0.16 (+3.16%) As of 09/9/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. QTTB, FNCH, AYTU, ALVR, CING, ABP, LSTA, CARM, LIXT, and IXHLShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Q32 Bio (QTTB), Finch Therapeutics Group (FNCH), Aytu BioPharma (AYTU), AlloVir (ALVR), Cingulate (CING), Abpro (ABP), Lisata Therapeutics (LSTA), Carisma Therapeutics (CARM), Lixte Biotechnology (LIXT), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Its Competitors Q32 Bio Finch Therapeutics Group Aytu BioPharma AlloVir Cingulate Abpro Lisata Therapeutics Carisma Therapeutics Lixte Biotechnology Incannex Healthcare Q32 Bio (NASDAQ:QTTB) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends. Does the media prefer QTTB or SLXN? In the previous week, Silexion Therapeutics had 2 more articles in the media than Q32 Bio. MarketBeat recorded 3 mentions for Silexion Therapeutics and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.80 beat Silexion Therapeutics' score of 0.66 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silexion Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of QTTB or SLXN? 31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are owned by institutional investors. 40.0% of Q32 Bio shares are owned by company insiders. Comparatively, 6.0% of Silexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, QTTB or SLXN? Silexion Therapeutics has lower revenue, but higher earnings than Q32 Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio$1.16M18.72-$47.73M-$4.30-0.41Silexion TherapeuticsN/AN/A-$16.44MN/AN/A Which has more volatility & risk, QTTB or SLXN? Q32 Bio has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Do analysts rate QTTB or SLXN? Q32 Bio presently has a consensus target price of $12.17, suggesting a potential upside of 583.52%. Silexion Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 1,382.21%. Given Silexion Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silexion Therapeutics is more favorable than Q32 Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is QTTB or SLXN more profitable? Silexion Therapeutics' return on equity of 0.00% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A -2,709.70% -61.16% Silexion Therapeutics N/A N/A -355.74% SummaryQ32 Bio beats Silexion Therapeutics on 7 of the 12 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.19M$3.17B$5.83B$10.00BDividend YieldN/A2.28%5.28%4.53%P/E RatioN/A21.3475.6926.28Price / SalesN/A471.32544.78188.18Price / CashN/A45.5837.2059.76Price / Book-0.1410.0511.506.41Net Income-$16.44M-$53.33M$3.28B$270.56M7 Day Performance-29.13%1.39%1.42%3.13%1 Month Performance-38.52%11.91%11.28%9.74%1 Year Performance-96.98%13.21%59.03%28.17% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$5.06-28.7%$75.00+1,382.2%-96.2%$5.19MN/A0.00N/AHigh Trading VolumeQTTBQ32 Bio2.6251 of 5 stars$1.74+1.5%$12.17+601.2%-96.1%$21.17M$1.16M-0.4039Gap DownFNCHFinch Therapeutics Group0.5084 of 5 stars$13.00flatN/A+1.0%$20.88MN/A-1.47190Negative NewsGap DownAYTUAytu BioPharma3.8216 of 5 stars$2.31-1.9%$10.00+333.8%-4.1%$20.70M$81M-3.20160Short Interest ↓ALVRAlloVirN/A$4.08+14.6%N/A-72.9%$20.58MN/A-0.20110Gap DownHigh Trading VolumeCINGCingulate3.0399 of 5 stars$3.74-6.4%$26.25+602.8%-29.7%$20.21MN/A-0.9120ABPAbproN/A$0.25+2.8%$4.00+1,487.3%N/A$20.20M$180K0.0015Gap DownLSTALisata Therapeutics2.9824 of 5 stars$2.22-4.5%$23.50+960.9%-27.4%$19.40M$1M-0.9930Gap DownCARMCarisma Therapeutics2.2991 of 5 stars$0.46+113.5%$1.93+319.4%-59.0%$19.27M$19.63M-0.3020Negative NewsShort Interest ↑Gap DownHigh Trading VolumeLIXTLixte Biotechnology0.8678 of 5 stars$4.19-5.9%N/A+147.4%$19.02MN/A-3.234IXHLIncannex Healthcare0.6219 of 5 stars$0.62-5.8%N/A-66.1%$18.22M$10K-0.513Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies Q32 Bio Alternatives Finch Therapeutics Group Alternatives Aytu BioPharma Alternatives AlloVir Alternatives Cingulate Alternatives Abpro Alternatives Lisata Therapeutics Alternatives Carisma Therapeutics Alternatives Lixte Biotechnology Alternatives Incannex Healthcare Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
